Ultragenyx Pharmaceutical Inc (RARE)
42.75
-0.45
(-1.04%)
USD |
NASDAQ |
May 03, 16:00
42.79
+0.04
(+0.09%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Investing (Quarterly): -107.02M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -107.02M |
| September 30, 2023 | 64.30M |
| June 30, 2023 | 99.42M |
| March 31, 2023 | 111.30M |
| December 31, 2022 | -171.60M |
| September 30, 2022 | -161.86M |
| June 30, 2022 | 79.17M |
| March 31, 2022 | -37.36M |
| December 31, 2021 | 69.06M |
| September 30, 2021 | -40.76M |
| June 30, 2021 | -41.25M |
| March 31, 2021 | -182.42M |
| December 31, 2020 | 97.90M |
| September 30, 2020 | -95.76M |
| June 30, 2020 | -86.14M |
| March 31, 2020 | -95.12M |
| December 31, 2019 | 67.27M |
| September 30, 2019 | 79.31M |
| June 30, 2019 | -58.43M |
| March 31, 2019 | -101.19M |
| December 31, 2018 | 73.56M |
| September 30, 2018 | 16.20M |
| Date | Value |
|---|---|
| June 30, 2018 | -52.07M |
| March 31, 2018 | -71.03M |
| December 31, 2017 | 57.39M |
| September 30, 2017 | 29.79M |
| June 30, 2017 | -21.08M |
| March 31, 2017 | -10.62M |
| December 31, 2016 | -7.153M |
| September 30, 2016 | 52.51M |
| June 30, 2016 | 23.99M |
| March 31, 2016 | 21.78M |
| December 31, 2015 | -33.56M |
| September 30, 2015 | -143.72M |
| June 30, 2015 | -111.01M |
| March 31, 2015 | -4.065M |
| December 31, 2014 | -17.02M |
| September 30, 2014 | -13.54M |
| June 30, 2014 | -27.48M |
| March 31, 2014 | -65.40M |
| December 31, 2013 | 11.11M |
| September 30, 2013 | -0.787M |
| June 30, 2013 | -42.96M |
| March 31, 2013 | -15.10M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-182.42M
Minimum
Mar 2021
111.30M
Maximum
Mar 2023
-21.58M
Average
-40.76M
Median
Sep 2021
Cash from Investing (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 17.10M |
| Madrigal Pharmaceuticals Inc | -362.12M |
| Sarepta Therapeutics Inc | 218.80M |
| FibroGen Inc | 10.24M |
| Rocket Pharmaceuticals Inc | -140.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -83.90M |
| Cash from Financing (Quarterly) | 330.61M |
| Free Cash Flow | -521.57M |
| Free Cash Flow Per Share (Quarterly) | -1.053 |
| Free Cash Flow to Equity (Quarterly) | -85.50M |
| Free Cash Flow to Firm (Quarterly) | -76.98M |
| Free Cash Flow Yield | -16.59% |